AR091273A1 - Inhibidores de pirimidinil tirosina quinasa - Google Patents
Inhibidores de pirimidinil tirosina quinasaInfo
- Publication number
- AR091273A1 AR091273A1 ARP130101980A AR091273A1 AR 091273 A1 AR091273 A1 AR 091273A1 AR P130101980 A ARP130101980 A AR P130101980A AR 091273 A1 AR091273 A1 AR 091273A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- nitrogen
- sulfur
- oxygen
- monocyclic heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Abstract
Reivindicación 1: Un compuesto de fórmula (1) o una de sus sales aceptables desde el punto de vista farmacéutico, en donde: cada R¹ es en forma independiente hidrógeno, un grupo alifático C₁₋₆ sustituido en forma opcional, un grupo heterocíclico monocíclico de 3 - 7 miembros sustituido en forma opcional, o un grupo heterocicloalquilo sustituido en forma opcional que tiene 3 - 7 átomos de carbono y 1 - 3 heteroátomos seleccionados en forma independiente de nitrógeno, oxígeno, o azufre; o dos grupos R¹ se toman junto con sus átomos intervinientes para formar un anillo heterocíclico monocíclico parcialmente insaturado o saturado de 3 - 7 miembros sustituido en forma opcional que tiene 1 - 2 heteroátomos seleccionados en forma independiente de nitrógeno, oxígeno, o azufre; en donde los grupos opcionalmente sustituidos pueden sustituirse con halógeno, -NO₂, -CN, -OR, -SR, -N(R)₂, -C(O)R, -CO₂R, -N(R)C(O)OR, -C(O)N(R)₂, -OC(O)R, -N(R)C(O)R, -S(O)R, -S(O)₂R, o -S(O)₂N(R)₂; cada R es en forma independiente hidrógeno o alifático C₁₋₆; o dos grupos R unidos al mismo nitrógeno se toman junto con sus átomos intervinientes para formar un anillo heterocíclico monocíclico parcialmente insaturado o saturado de 3 - 7 miembros sustituido en forma opcional que tiene 1 - 2 heteroátomos, en los cuales un segundo heteroátomo se selecciona en forma independiente de nitrógeno, oxígeno, o azufre; el Anillo A es un compuesto de fórmula (2); R² es -Cl o -F; y R³ es -CF₃, -OCF₃, o -F.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261657360P | 2012-06-08 | 2012-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR091273A1 true AR091273A1 (es) | 2015-01-21 |
Family
ID=49712704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101980 AR091273A1 (es) | 2012-06-08 | 2013-06-05 | Inhibidores de pirimidinil tirosina quinasa |
Country Status (30)
Country | Link |
---|---|
US (5) | US9394277B2 (es) |
EP (3) | EP2858499B1 (es) |
JP (6) | JP6214643B2 (es) |
KR (4) | KR102468430B1 (es) |
CN (3) | CN104540385B (es) |
AR (1) | AR091273A1 (es) |
AU (5) | AU2013271407B2 (es) |
BR (2) | BR112014030655B1 (es) |
CA (2) | CA2875799C (es) |
CY (1) | CY1120638T1 (es) |
DK (1) | DK2858499T3 (es) |
EA (2) | EA027823B1 (es) |
ES (2) | ES2834333T3 (es) |
HK (1) | HK1209284A1 (es) |
HR (1) | HRP20181294T1 (es) |
HU (1) | HUE039897T2 (es) |
IL (2) | IL235938B (es) |
IN (1) | IN2014DN10576A (es) |
LT (1) | LT2858499T (es) |
MX (2) | MX363672B (es) |
NZ (1) | NZ702715A (es) |
PH (2) | PH12014502699A1 (es) |
PL (1) | PL2858499T3 (es) |
PT (1) | PT2858499T (es) |
RS (1) | RS57978B1 (es) |
SG (2) | SG11201408173WA (es) |
SI (1) | SI2858499T1 (es) |
TW (3) | TWI719209B (es) |
WO (1) | WO2013185084A1 (es) |
ZA (1) | ZA201409255B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5699149B2 (ja) | 2009-09-04 | 2015-04-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Bruton型チロシンキナーゼ阻害薬 |
EP2632898A4 (en) | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | HETEROCYCLIC TYROSINE KINASE HEMMER |
US9353087B2 (en) | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
LT3080103T (lt) * | 2013-12-11 | 2018-08-10 | Biogen Ma Inc. | Biarilo junginiai, tinkami panaudoti žmogaus ligų gydymui onkologijoje, neurologijoje ir imunologijoje |
WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
ME03807B (me) | 2014-10-24 | 2021-04-20 | Bristol Myers Squibb Co | Jedinjenja indol karboksamida korisna kao inhibitori kinaze |
RU2019104758A (ru) * | 2016-07-21 | 2020-08-21 | Байоджен Ма Инк. | Сукцинатные формы и композиции ингибиторов тирозинкиназы брутона |
WO2019208805A1 (ja) | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Btk阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および/または治療剤 |
KR102545594B1 (ko) | 2018-07-31 | 2023-06-21 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
WO2023081709A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Vecabrutinib for the treatment of graft-versus-host disease |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1624A (en) * | 1840-06-10 | Cooking-stove | ||
US4528138A (en) | 1984-06-20 | 1985-07-09 | E. R. Squibb & Sons, Inc. | 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6919178B2 (en) | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
NZ521248A (en) | 2000-03-17 | 2004-04-30 | Bristol Myers Squibb Pharma Co | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha |
MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
ATE423120T1 (de) | 2000-06-26 | 2009-03-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe |
PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
AU2002363236A1 (en) * | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
EP1442039A1 (en) | 2001-10-31 | 2004-08-04 | Bayer HealthCare AG | Pyrimido (4,5-b) indole derivatives |
GEP20084540B (en) | 2003-01-14 | 2008-11-25 | Arena Pharm Inc | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
US7326712B2 (en) | 2003-10-14 | 2008-02-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Substituted tricyclic compounds as protein kinase inhibitors |
US20080253960A1 (en) * | 2004-04-01 | 2008-10-16 | The Trustees Of The University Of Pennsylvania Center For Technology Transfer | Lipoprotein-Based Nanoplatforms |
AU2005249380C1 (en) | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
TW200621760A (en) | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
ZA200704476B (en) * | 2004-11-04 | 2008-09-25 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
NZ555320A (en) | 2004-12-03 | 2010-11-26 | Schering Corp | Substituted piperazines as CB1 antagonists |
ATE543821T1 (de) | 2004-12-28 | 2012-02-15 | Exelixis Inc | Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen |
WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
US20060281700A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
RU2597364C2 (ru) | 2005-11-01 | 2016-09-10 | Таргеджен, Инк. | Би-арил-мета-пиримидиновые ингибиторы киназ |
US20070142369A1 (en) * | 2005-12-21 | 2007-06-21 | Margaret Van Heek | Combination of an H3 antagonist/inverse agonist and an appetite suppressant |
US20080076924A1 (en) | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
WO2008014307A2 (en) | 2006-07-26 | 2008-01-31 | Novartis Ag | Inhibitors of undecaprenyl pyrophosphate synthase |
EP2068849A2 (en) * | 2006-09-11 | 2009-06-17 | CGI Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
SI2530083T1 (sl) | 2006-09-22 | 2016-09-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
JP2010520199A (ja) * | 2007-03-02 | 2010-06-10 | シェーリング コーポレイション | ピペリジン誘導体およびその使用方法 |
CN101730699A (zh) | 2007-03-21 | 2010-06-09 | 百时美施贵宝公司 | 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物 |
WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
US8093239B2 (en) | 2007-06-01 | 2012-01-10 | Glaxosmithkline Llc | Imidazopyridine kinase inhibitors |
AU2009211514B2 (en) * | 2008-02-05 | 2014-02-20 | F. Hoffmann-La Roche Ag | Novel pyridinones and pyridazinones |
CA2760044A1 (en) | 2008-04-29 | 2009-11-05 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
WO2010068788A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
MX2011006171A (es) * | 2008-12-19 | 2011-06-20 | Squibb Bristol Myers Co | Compuestos de carbazol carboxamida utiles como inhibidores de cinasa. |
US9266890B2 (en) * | 2009-01-06 | 2016-02-23 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
WO2010136422A1 (de) | 2009-05-25 | 2010-12-02 | Sandoz Ag | Verfahren zur herstellung von ceftobiprol medocaril |
JP5699149B2 (ja) | 2009-09-04 | 2015-04-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Bruton型チロシンキナーゼ阻害薬 |
WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
US8685880B2 (en) | 2010-06-30 | 2014-04-01 | Chevron U.S.A. Inc. | On-site drying of aqueous salt for ionic liquid make-up |
EP2632898A4 (en) | 2010-10-29 | 2014-04-02 | Biogen Idec Inc | HETEROCYCLIC TYROSINE KINASE HEMMER |
US9353087B2 (en) | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
WO2015089327A1 (en) | 2013-12-11 | 2015-06-18 | Biogen Idec Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
LT3080103T (lt) | 2013-12-11 | 2018-08-10 | Biogen Ma Inc. | Biarilo junginiai, tinkami panaudoti žmogaus ligų gydymui onkologijoje, neurologijoje ir imunologijoje |
WO2016054627A1 (en) | 2014-10-03 | 2016-04-07 | Ohio State Innovation Foundation | Biomarkers of bruton tyrosine kinase inhibitor resistance |
-
2013
- 2013-06-05 AR ARP130101980 patent/AR091273A1/es not_active Application Discontinuation
- 2013-06-07 JP JP2015516256A patent/JP6214643B2/ja active Active
- 2013-06-07 SG SG11201408173WA patent/SG11201408173WA/en unknown
- 2013-06-07 AU AU2013271407A patent/AU2013271407B2/en active Active
- 2013-06-07 TW TW106116775A patent/TWI719209B/zh active
- 2013-06-07 HU HUE13800042A patent/HUE039897T2/hu unknown
- 2013-06-07 CA CA2875799A patent/CA2875799C/en active Active
- 2013-06-07 SG SG10201708535UA patent/SG10201708535UA/en unknown
- 2013-06-07 IN IN10576DEN2014 patent/IN2014DN10576A/en unknown
- 2013-06-07 EP EP13800042.7A patent/EP2858499B1/en active Active
- 2013-06-07 TW TW102120447A patent/TWI592406B/zh active
- 2013-06-07 EA EA201492056A patent/EA027823B1/ru unknown
- 2013-06-07 EA EA201790418A patent/EA201790418A1/ru unknown
- 2013-06-07 MX MX2014015044A patent/MX363672B/es unknown
- 2013-06-07 DK DK13800042.7T patent/DK2858499T3/en active
- 2013-06-07 KR KR1020217017552A patent/KR102468430B1/ko active IP Right Grant
- 2013-06-07 EP EP20186539.1A patent/EP3753934A1/en active Pending
- 2013-06-07 EP EP18171833.9A patent/EP3385263B1/en active Active
- 2013-06-07 ES ES18171833T patent/ES2834333T3/es active Active
- 2013-06-07 PT PT13800042T patent/PT2858499T/pt unknown
- 2013-06-07 NZ NZ702715A patent/NZ702715A/en unknown
- 2013-06-07 CN CN201380036869.5A patent/CN104540385B/zh active Active
- 2013-06-07 WO PCT/US2013/044800 patent/WO2013185084A1/en active Application Filing
- 2013-06-07 KR KR1020207010675A patent/KR20200043497A/ko active Application Filing
- 2013-06-07 SI SI201331130T patent/SI2858499T1/sl unknown
- 2013-06-07 US US14/406,315 patent/US9394277B2/en active Active
- 2013-06-07 TW TW110102365A patent/TWI792158B/zh active
- 2013-06-07 BR BR112014030655-9A patent/BR112014030655B1/pt active IP Right Grant
- 2013-06-07 CN CN201810384098.3A patent/CN109305959B/zh active Active
- 2013-06-07 CN CN202110783143.4A patent/CN113549055A/zh active Pending
- 2013-06-07 PL PL13800042T patent/PL2858499T3/pl unknown
- 2013-06-07 KR KR1020157000393A patent/KR102102587B1/ko active IP Right Grant
- 2013-06-07 BR BR122021002178-3A patent/BR122021002178B1/pt active IP Right Grant
- 2013-06-07 KR KR1020227039393A patent/KR20220154850A/ko not_active Application Discontinuation
- 2013-06-07 ES ES13800042.7T patent/ES2684268T3/es active Active
- 2013-06-07 LT LTEP13800042.7T patent/LT2858499T/lt unknown
- 2013-06-07 CA CA3108186A patent/CA3108186A1/en not_active Abandoned
- 2013-06-07 RS RS20180950A patent/RS57978B1/sr unknown
-
2014
- 2014-11-27 IL IL235938A patent/IL235938B/en active IP Right Grant
- 2014-12-03 PH PH12014502699A patent/PH12014502699A1/en unknown
- 2014-12-08 MX MX2019003618A patent/MX2019003618A/es unknown
- 2014-12-15 ZA ZA2014/09255A patent/ZA201409255B/en unknown
-
2015
- 2015-10-20 HK HK15110301.6A patent/HK1209284A1/xx unknown
-
2016
- 2016-06-29 US US15/196,389 patent/US9944622B2/en active Active
-
2017
- 2017-03-07 AU AU2017201536A patent/AU2017201536B2/en active Active
- 2017-08-03 JP JP2017150480A patent/JP2017193583A/ja not_active Withdrawn
-
2018
- 2018-03-05 US US15/911,546 patent/US10618887B2/en active Active
- 2018-07-09 PH PH12018501463A patent/PH12018501463A1/en unknown
- 2018-08-08 HR HRP20181294TT patent/HRP20181294T1/hr unknown
- 2018-08-16 CY CY181100861T patent/CY1120638T1/el unknown
-
2019
- 2019-02-04 JP JP2019017850A patent/JP2019077728A/ja not_active Withdrawn
- 2019-05-17 AU AU2019203476A patent/AU2019203476B2/en active Active
-
2020
- 2020-02-27 US US16/802,959 patent/US20210017155A1/en not_active Abandoned
- 2020-10-11 IL IL277951A patent/IL277951A/en unknown
-
2021
- 2021-02-08 JP JP2021018127A patent/JP2021073298A/ja active Pending
- 2021-02-08 JP JP2021018128A patent/JP2021073299A/ja active Pending
- 2021-04-21 AU AU2021202412A patent/AU2021202412A1/en not_active Abandoned
-
2022
- 2022-08-08 US US17/883,202 patent/US20230174511A1/en active Pending
- 2022-11-25 AU AU2022275504A patent/AU2022275504A1/en active Pending
-
2023
- 2023-01-16 JP JP2023004462A patent/JP2023052415A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR091273A1 (es) | Inhibidores de pirimidinil tirosina quinasa | |
CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
CO2019003349A2 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
CY1120705T1 (el) | Καινοφανεις αναστολεις αποακετυλασων ιστονων | |
CU24517B1 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
AR090928A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina heterociclicos sustituidos | |
AR107694A1 (es) | Heteroarilos inhibidores de pad4 | |
AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
AR093598A1 (es) | Compuestos y sus metodos de empleo | |
UY35573A (es) | Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
CR20140548A (es) | Derivados de aril-sultamo como moduladores de rorc | |
AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
CR20200276A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059) | |
EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
AR094852A1 (es) | Oestra-1,3,5(10),16-tetraeno-3-carboxamidas | |
AR098432A1 (es) | Compuestos heterocíclicos | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
CU20170007A7 (es) | Compuestos de imidazopiridazina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |